Abstract
Tuberculosis subunit vaccines codelivered with interleukin-12 (IL-12)-encapsulated microspheres (IL-12EM) are designed for a sustained release of IL-12 and could induce strong Th1 immune responses specific to Ag85A and ESAT-6. The adjuvant combination of IL-12EM plus AS01B was a more efficient way to induce a sustained Th1 immunity and protection against Mycobacterium tuberculosis.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acyltransferases / immunology
-
Adjuvants, Immunologic*
-
Animals
-
Antibodies, Bacterial / blood*
-
Antibodies, Bacterial / immunology
-
Antigens, Bacterial / immunology
-
Bacterial Proteins
-
Capsules
-
Delayed-Action Preparations
-
Interleukin-12 / immunology*
-
Mice
-
Mice, Inbred C57BL
-
Microspheres*
-
Mycobacterium tuberculosis / immunology
-
Mycobacterium tuberculosis / pathogenicity
-
Th1 Cells / immunology
-
Tuberculosis / immunology
-
Tuberculosis / prevention & control*
-
Tuberculosis Vaccines / administration & dosage
-
Tuberculosis Vaccines / immunology*
-
Vaccination
Substances
-
Adjuvants, Immunologic
-
Antibodies, Bacterial
-
Antigens, Bacterial
-
Bacterial Proteins
-
Capsules
-
Delayed-Action Preparations
-
ESAT-6 protein, Mycobacterium tuberculosis
-
Tuberculosis Vaccines
-
Interleukin-12
-
Acyltransferases
-
antigen 85A, Mycobacterium tuberculosis